Protein Metabolism Clinical Trial
Official title:
Arginine Feeding: a Novel Strategy to Improve Protein Metabolism in Cancer and the Response to Surgery
Verified date | April 2019 |
Source | Texas A&M University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Muscle catabolism is a major problem in cancer patients undergoing surgery as it negatively affects post-operative recovery. Recent evidence exists that protein metabolic changes are already apparent in cancer before muscle wasting is being present. In line, patients with breast cancer, generally characterized by a normal nutritional status, were recently found to be arginine deficient. Arginine deficiency in cancer can be explained by: 1) Reduced arginine availability, due to exhaustion of endogenous (muscle) sources of arginine 2) Enhanced arginine catabolism, due to conversion of arginine by arginase, which is abundant in tumors. Protein is the most important endogenous source of arginine. Arginine deficiency will lead to a negative feedback loop in cachexia by promoting protein breakdown in an attempt to restore plasma arginine levels. We hypothesize that pre-operative arginine supplementation in breast cancer patients diminishes the occurrence of muscle wasting after surgery by 1) normalizing arginine availability pre-operatively, resulting in conservation of protein, 2) diminishing the catabolic effects of surgery by supplying exogenous arginine for the post-operative response, 3) enhancing the anabolic capacity to feeding through supplying substrate for protein synthesis.
Status | Active, not recruiting |
Enrollment | 32 |
Est. completion date | February 2021 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 30 Years and older |
Eligibility |
Inclusion Criteria: Cancer groups (for aims 1 and 2) 1. Recently diagnosed (up to 4 weeks prior to treatment for cancer) with stage I, II or III invasive breast cancer 2. Undergoing mastectomy 3. Age greater than 30 years 4. Ability to sign informed consent 5. Good performance status defined by ECOG scale 0,1 or 2 (see CRF performance status) Control group (for aim 1) 1. Age greater than 30 years 2. Undergoing prophylactic mastectomy 3. Ability to sign informed consent 4. Good performance status defined by ECOG scale 0,1 or 2 (see CRF performance status) Exclusion Criteria: All groups (aim 1 and 2) 1. Body weight loss of greater than 10% in the past 3 months 2. Previous anti-cancer therapy (e.g. chemotherapy or radiotherapy) or surgery less than 4 weeks prior to the experiment 3. Diagnosed diabetes type I or II 4. Untreated metabolic diseases including liver or renal disease 5. Any documented autoimmune disease 6. Use of corticosteroids, beta-antagonists or nitrovasodilators 7. Use of supplements enriched with amino acids 8. Presence of acute illness or metabolically unstable chronic illness 9. Unstable heart disease requiring therapy or recent myocardial infarction (less than 1 year) 10. Current alcohol or drug abuse (ETOH more than 2 servings per day) 11. Allergy/intolerance to any of the ingredients of the study products 12. Any other condition deemed by the PI and the study physician as exclusion or that interferes with proper conduct of the study/ safety of the patient. |
Country | Name | City | State |
---|---|---|---|
United States | University of Arkansas for Medical Sciences | Little Rock | Arkansas |
Lead Sponsor | Collaborator |
---|---|
Texas A&M University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Net protein balance | end of study | ||
Secondary | Arginine turnover | end of study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01143493 -
The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease
|
||
Active, not recruiting |
NCT01461603 -
Local Effects of Amino Acids and 3-hydroxybutyrate in the Bilaterally Perfused Human Leg
|
N/A | |
Completed |
NCT04422665 -
Preventing Bed-rest Induced Muscle Loss in the Elderly
|
N/A | |
Completed |
NCT04121689 -
Time Course of Postprandial Protein Metabolism
|
N/A | |
Completed |
NCT01820702 -
Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation
|
N/A | |
Completed |
NCT03142737 -
Are the "Ounce-equivalents" in the Protein Foods Groups Really Equivalent?
|
N/A | |
Completed |
NCT03952884 -
Skeletal Muscle Protein Synthetic Response to Amino Acid and Peptides
|
N/A | |
Completed |
NCT05197140 -
Role of the Protein Matrix in the Anabolic Response to a Ground Beef Patty as Opposed to the Impossible (Vegi-) Burger
|
N/A | |
Completed |
NCT04821557 -
Effect of Microbial Protease Supplementation on Postprandial Amino Acid Levels
|
N/A | |
Recruiting |
NCT05400733 -
Prandial Metabolic Phenotype in Adults
|
N/A | |
Terminated |
NCT00586807 -
Metabolic Response to Infliximab in Pediatric Ulcerative Colitis
|
N/A | |
Completed |
NCT01276795 -
Whey Protein-based Enteral Nutrition Support to Improve Protein Economy in Surgical Patients
|
N/A | |
Completed |
NCT00586352 -
Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT03037294 -
Protein Turnover in the Osteoarthritic Knee
|
N/A | |
Completed |
NCT01509456 -
The Effect of Potassium Bicarbonate on Bone and Several Physiological Systems During Immobilisation
|
N/A | |
Completed |
NCT00583232 -
Protein and Energy Metabolism in Pediatric Crohn's Disease
|
Phase 1 | |
Completed |
NCT03179462 -
"Ounce-equivalents" in the Protein Foods Group: Benefits of Quality
|
N/A | |
Completed |
NCT03326284 -
Optimal Protein Dose Per Meal During Weight Loss in Perspective to Maintaining Muscle Mass
|
N/A | |
Completed |
NCT03147001 -
Protein Ingestion Before Training Low
|
N/A |